

# Sebastian Ewen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1420640/publications.pdf>

Version: 2024-02-01

45  
papers

2,093  
citations

394421

19  
h-index

243625

44  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization. PLoS ONE, 2022, 17, e0266069.	2.5	0
2	Valvular heart disease in patients with chronic kidney disease. Herz, 2021, 46, 228-233.	1.1	10
3	Echocardiographic assessment of mitral regurgitation: discussion of practical and methodologic aspects of severity quantification to improve diagnostic conclusiveness. Clinical Research in Cardiology, 2021, 110, 1704-1733.	3.3	12
4	SARS-CoV-2 vaccination in cardiothoracic organ transplant recipients: effective strategies wanted. Clinical Research in Cardiology, 2021, 110, 1139-1141.	3.3	0
5	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. European Journal of Heart Failure, 2021, 23, 1960-1970.	7.1	14
6	Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death. Herzschrittmachertherapie Und Elektrophysiologie, 2021, , 1.	0.8	0
7	The Current Status of Devices for the Treatment of Resistant Hypertension. American Journal of Hypertension, 2020, 33, 10-18.	2.0	9
8	Expert consensus document on the assessment of the severity of aortic valve stenosis by echocardiography to provide diagnostic conclusiveness by standardized verifiable documentation. Clinical Research in Cardiology, 2020, 109, 271-288.	3.3	19
9	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clinical Research in Cardiology, 2020, 109, 845-856.	3.3	24
10	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. Clinical Research in Cardiology, 2020, 109, 1500-1506.	3.3	50
11	Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic. Clinical Research in Cardiology, 2020, 109, 1507-1509.	3.3	0
12	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal of the American College of Cardiology, 2020, 75, 1017-1028.	2.8	70
13	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. JACC: Case Reports, 2020, 2, 384-388.	0.6	2
14	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	2.2	189
15	Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. Journal of the American Heart Association, 2019, 8, e011183.	3.7	28
16	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. Cardiovascular Revascularization Medicine, 2018, 19, 845-851.	0.8	11
17	Real-time left ventricular pressure-volume loops during percutaneous central arteriovenous anastomosis. European Heart Journal, 2018, 39, 2330-2331.	2.2	8
18	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. Clinical Research in Cardiology, 2018, 107, 642-652.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Spontaneous mitral annular rupture. <i>European Heart Journal - Case Reports</i> , 2018, 2, yty097.	0.6	0
20	Hypertension: history and development of established and novel treatments. <i>Clinical Research in Cardiology</i> , 2018, 107, 16-29.	3.3	18
21	Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 122, 34-46.	1.9	9
22	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. <i>EuroIntervention</i> , 2018, 14, 121-128.	3.2	19
23	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. <i>EuroIntervention</i> , 2018, 14, e598-e602.	3.2	3
24	Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. <i>EuroIntervention</i> , 2018, 14, e603-e606.	3.2	2
25	Long-Term Follow-Up of Baroreflex Activation Therapy in Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 782-784.	2.7	3
26	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017, 241, 373-378.	1.7	23
27	Hypertension up to date: SPRINT to SPYRAL. <i>Clinical Research in Cardiology</i> , 2017, 106, 475-484.	3.3	18
28	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	56
29	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	13.7	597
30	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. <i>Korean Circulation Journal</i> , 2017, 47, 9.	1.9	11
31	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
32	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. <i>Journal of Hypertension</i> , 2016, 34, 2475-2479.	0.5	8
33	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPPLICITY HTN-3 and the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2016, 38, ehw325.	2.2	104
34	Renal Denervation Induces Reverse Remodeling in MicroRNA: Just Blood Pressure Reduction or More?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 495-496.	2.0	0
35	Anatomical and procedural determinants of catheter-based renal denervation. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 474-479.	0.8	13
36	Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. <i>Biomarkers in Medicine</i> , 2016, 10, 841-851.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Renal denervation in patients with heart failure with preserved ejection fraction: end of the beginning?. <i>European Journal of Heart Failure</i> , 2016, 18, 713-715.	7.1	2
38	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1766-1775.	2.8	168
39	Analyses of drugs stored at home by elderly patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2015, 104, 320-327.	3.3	23
40	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 1097-1105.	3.3	76
41	Drug adherence in patients taking oral anticoagulation therapy. <i>Clinical Research in Cardiology</i> , 2014, 103, 173-182.	3.3	42
42	Effects of Renal Sympathetic Denervation on Exercise Blood Pressure, Heart Rate, and Capacity in Patients With Resistant Hypertension. <i>Hypertension</i> , 2014, 63, 839-845.	2.7	24
43	Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 430.	3.5	6
44	First-in-human experience: percutaneous renal denervation through a false lumen fenestration in aortic dissection type B. <i>EuroIntervention</i> , 2013, 8, 1110-1110.	3.2	4
45	Response and non-response to renal denervation: who is the ideal candidate?. <i>EuroIntervention</i> , 2013, 9, R54-R57.	3.2	35